Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | PGD | P52209 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10476484 | 0.85 | ALDH1A1 (0.46) | TSHRALDH1A1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL6523961 | 0.85 | ALDH1A1 (0.46) | TSHRALDH1A1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL20742048 | 0.81 | TSHR (0.43) | TSHRSLC1A3SLC1A2SLC1A1PGD | |
| SCHEMBL1794070 | 0.79 | TSHR (0.41) | TSHR | |
| SCHEMBL14498319 | 0.79 | ALDH1A1 (0.46) | ALDH1A1SLC1A3SLC1A2SLC1A1TP53 | |
| SCHEMBL9437852 | 0.77 | TSHR (0.39) | TSHRPGD | |
| Benzene SCHEMBL9474100 | 0.76 | TSHR (0.38) | TSHRTP53 | |
| SCHEMBL596399 | 0.73 | TSHR (0.39) | TSHRSLC1A3SLC1A2SLC1A1TP53 | |
| SCHEMBL7290471 | 0.70 | SLC1A3 (0.54) | TSHRSLC1A3SLC1A2SLC1A1TP53 | |
| SCHEMBL722389 | 0.70 | SLC1A3 (0.54) | TSHRSLC1A3SLC1A2SLC1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030065173-A1 | Pyridone-fused azabicyclic- or cytisine derivatives, their preparation and their use in addiction therapy | O'NEILL BRIAN T (US) | 2003-04-03 | — | — | US | claimed |
| WO-2024128359-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF BONE DISEASES | 전남대학교산학협력단 | 2024-06-20 | — | — | WO | disclosed |
| WO-2024128335-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BONE DISEASES | 전남대학교산학협력단 | 2024-06-20 | — | — | WO | disclosed |
| EP-2155719-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | Wyeth LLC (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008147945-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-12-04 | — | — | WO | disclosed |
| US-20080280981-A1 | Tranexamic acid formulations | XANODYNE PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080146844-A1 | PROCESS FOR PREPARING TOLTERODINE | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-06-19 | — | — | US | disclosed |
| US-7355077-B2 | Process for preparing tolterodine | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-04-08 | — | — | US | disclosed |
| US-20060094904-A1 | Reacting methyl 3-(2-benzyloxy-5-methyl phenyl)-3-phenylpropionate with a reducing agent to form 3-(2-benzyloxy-5-methylphenyl)-3-phenylpropanol | DR. REDDY'S LABORATORIES LIMITED (IN) | 2006-05-04 | — | — | US | disclosed |
| EP-1592661-A2 | CYCLOPROPYL BETA-AMINO ACID DERIVATIVES | Warner-Lambert Company LLC (US) | 2005-11-09 | — | — | EP | disclosed |
| WO-1995002607-A1 | 7-SUBSTITUTED-Δ4-6-AZASTEROID DERIVATIVES AS 5α-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1995-01-26 | — | — | WO | disclosed |
| WO-1994021614-A1 | SUBSTITUTED 3-PHENANTHRIDINONE DERIVATIVES AS 5α-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1994-09-29 | — | — | WO | disclosed |
| WO-1994014438-A1 | HYDANTOIN AND SUCCINIMIDE-SUBSTITUTED DERIVATIVES OF SPIROINDANYLCAMPHORSULFONYL OXYTOCIN ANTAGONISTS | MERCK & CO., INC. (US) | 1994-07-07 | — | — | WO | disclosed |
| WO-1994007496-A1 | TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1994-04-14 | — | — | WO | disclosed |
| WO-1993006092-A1 | PIPERAZINYL (SULFONYL)AMIDE DERIVATIVES OF CAMPHOR AS OXYTOCIN ANTAGONISTS | MERCK & CO., INC. (US) | 1993-04-01 | — | — | WO | disclosed |
| US-5137904-A | Useful in the treatment of atherosclerosis and thrombosis | G. D. SEARLE & CO. (US) | 1992-08-11 | — | — | US | disclosed |
| EP-0486280-A2 | Piperidinylcamphorsulfonyl oxytocin antagonists | MERCK & CO. INC. (US) | 1992-05-20 | — | — | EP | disclosed |
| WO-1992007821-A1 | DIASTEREOISOMERS OF BICYCLO-SUBSTITUTED PHENYLACETONITRILE DERIVATIVES | G.D. SEARLE & CO. (US) | 1992-05-14 | — | — | WO | disclosed |
| CN-87107723-A | Agent of dihydropyridine anti-allergy and anti-inflammatory agent | — | 1988-05-18 | — | — | CN | disclosed |
| US-4550105-A | BETA-LACTAMASE INHIBITORS, ANTIBIOTICS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1985-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146844-A1 | PROCESS FOR PREPARING TOLTERODINE | ADRA2B, ADRB3, ADRB1 | TSHR 81/4885ALDH1A1 2060/4885SLC1A3 4065/4885 |
| US-20030065173-A1 | Pyridone-fused azabicyclic- or cytisine derivatives, their preparation and their use in addiction therapy | CHRNA5, CHRNA4, CHRNA10 | TSHR 2084/4885ALDH1A1 488/4885SLC1A3 1355/4885 |
| US-20060094904-A1 | Reacting methyl 3-(2-benzyloxy-5-methyl phenyl)-3-phenylpropionate with a reducing agent to form 3-(2-benzyloxy-5-methylphenyl)-3-phenylpropanol | ADRB3, UGT1A3, COMT | TSHR 689/4885ALDH1A1 1360/4885SLC1A3 1885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.